|
1) Serruys PW, deJaegere P, Kiemeneij F, et al. on behalf of the Benestent study group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994; 331: 489-95
|
|
|
|
2) Ozaki Keane D, Serruys PW, et al. Six-month clinical and angiographic outcome of the new less shortening Wallstent in native coronary arteries. Circulation. 1996; 93: 2114-20
|
|
|
|
|
|
3) Ozaki Y, Violaris AG, Serruys PW, et al. Short- and long-term clinical and quantitative angiographic results with the new less shortening Wallstent for vessel reconstruction in chronic total occlusion. J Am Coll Cardiol. 1996; 28: 354-60
|
|
|
|
|
|
4) Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346: 1773-80
|
|
|
|
|
|
5) Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349: 1315-23
|
|
|
|
|
|
6) Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004; 350: 221-31
|
|
|
|
|
|
7) Aoki J, Nakazawa G, Tanabe K, et al. Incidence and clinical impact of coronary stent fracture after sirolimus-eluting stent implantation. Catheter Cardiovasc Interv. 2007; 69: 380-6
|
|
|
|
|
|
8) Lee MS, Jurewitz D, Aragon J, et al. Stent fracture associated with drug-eluting stents: Clinical characteristics and implications. Catheter Cardiovasc Interv. 2007; 69: 387-94
|
|
|
|
|
|
9) Okumura M, Ozaki Y, Ishii J, et al. Restenosis and stent fracture following sirolimus-eluting stent (SES) implantation: A serial quantitative coronary angiography (QCA) and intravascular ultrasound (IVUS) study. Circ J. 2007; 71: 1669- 77
|
|
|
|
|
10) Serruys PW, Degertekin M, Tababe K, et al. Intravascular ultrasound finding in the multicenter, randomized, double-blind RAVEL (Randomized study with the sirolimus-eluting Velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation. 2002; 106: 798-803
|
|
|
|
|
|
11) Cook P, Wenaweser P, Togni M, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation. 2007; 115: 2426-34
|
|
|
|
|
|
12) Ozaki Y, Okumura M, Ishii J, et al. Vulnerable and Stable Lesion Characteristics Assessed by Optical Coherence Tomography (OCT), Integrated-Backscatter Intracoronary Ultrasound (IB-IVUS), Angioscopy and 64-slice Multidetector CT (MDCT). J Am Coll Cardiol. 2007; 49 Suppl B: 27B
|
|
|
|
|
|
13) Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trial; a case for standardized definitions. Circulation. 2007; 115: 2344-51
|
|
|
|
|
|
14) Virmani R, Liistro F, Stankovic G, et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation. 2002; 106: 2649-51
|
|
|
|
|
|
15) Jeremias A, Sylvia B, Bridges J, et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation. 2004; 109: 1930-2
|
|
|
|
|
|
16) Moreno R, Fernandez C, Hernandez R, et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol. 2005; 45: 954-9
|
|
|
|
|
|
17) Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll cardiol. 2005; 45: 947-53
|
|
|
|
|
|
18) McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004; 364: 1519-21
|
|
|
|
|
|
19) Pfisterer M, Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents. J Am Coll Cardiol. 2006; 48: 2584-91
|
|
|
|
|
|
20) Bavry AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug eluting stents: A meta-analysis of randomized clinical trial. Am J Med. 2006; 119: 1056-61
|
|
|
|
|
|
21) Sousa JE, Costa MA, Abizaid A, et al. Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents. Circulation. 2005; 111: 2326-9
|
|
|
|
|
|
22) Morice MC, Serruys P, Costantini C, et al. Three-year follow-up of the RAVEL study: A randomized study with the sirolimus-eluting velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. J Am Coll Cardiol. 2004; 43: 87A
|
|
|
|
|
|
23) Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007; 356: 1030-9
|
|
|
|
|
|
24) Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007; 356: 1009-19
|
|
|
|
|
|
25) Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007; 369: 667-78
|
|
|
|
|